Kura Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Operating Activities | |||
| Net loss | $(278,666) | $(173,983) | $(152,631) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Share-based compensation expense | 37,108 | 33,897 | 28,082 |
| Amortization of premium and accretion of discounts on short-term investments, net | (8,488) | (13,141) | (9,420) |
| Depreciation expense | 1,032 | 848 | 849 |
| Non-cash interest expense | 515 | 523 | 477 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (6,744) | (2,060) | — |
| Inventory | (413) | — | — |
| Prepaid expenses and other current assets | (15,950) | (6,850) | (1,960) |
| Accounts payable | 4,499 | (1,627) | (924) |
| Accrued expenses and other current liabilities | 12,654 | 16,827 | 11,251 |
| Operating lease right-of-use and other long-term assets | (6,363) | 947 | (685) |
| Other long-term liabilities | 1,043 | 758 | 137 |
| Contract liabilities | 195,715 | 278,178 | — |
| Net cash (used in) provided by operating activities | (64,058) | 134,317 | (124,824) |
| Investing Activities | |||
| Purchases of short-term investments | (761,588) | (659,048) | (409,824) |
| Maturities of short-term investments | 755,128 | 557,930 | 425,549 |
| Purchases of property and equipment | (6,638) | (472) | (168) |
| Net cash (used in) provided by investing activities | (13,098) | (101,590) | 15,557 |
| Financing Activities | |||
| Proceeds from issuance of stock under equity plans | 1,793 | 8,604 | 1,206 |
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | — | 145,813 | 93,577 |
| Net cash provided by financing activities | 1,793 | 154,417 | 94,783 |
| Net (decrease) increase in cash and cash equivalents | (75,363) | 187,144 | (14,484) |
| Cash and cash equivalents at beginning of period | 224,462 | 37,318 | 51,802 |
| Cash and cash equivalents at end of period | $149,099 | $224,462 | $37,318 |
| Supplemental disclosure of cash flow information | |||
| Interest paid | $998 | $1,096 | $1,064 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.